Neurogene (NGNE) Non-Current Deferred Tax Liability (2013 - 2014)
Neurogene (NGNE) posted Non-Current Deferred Tax Liability of $1.8 million for Q4 2014, little changed on a QoQ basis from $1.8 million in Q1 2014, and little changed year-over-year from $1.8 million in Q4 2013.
Neurogene (NGNE) Non-Current Deferred Tax Liability (2013 - 2014) Analysis & Trends
Neurogene's Non-Current Deferred Tax Liability history runs 2 years deep, the most recent figure standing at $1.8 million for Q4 2014.
- Quarterly Non-Current Deferred Tax Liability changed 0.02% year-over-year to $1.8 million in Q4 2014, while the trailing twelve-month figure through Dec 2014 was $1.8 million (changed 0.02% YoY) and the FY2014 annual result came in at $1.8 million, changed 0.02% from the prior year.
- Non-Current Deferred Tax Liability was $1.8 million for Q4 2014 at Neurogene, roughly flat from $1.8 million in the prior quarter.
- Across five years, Non-Current Deferred Tax Liability topped out at $1.8 million in Q4 2013 and bottomed at $1.8 million in Q4 2014.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Neurogene | 17.50 Mn | 17.50 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2014 | 1.80 Mn |
| Dec 31, 2014 | 1.80 Mn |
| Mar 31, 2014 | 1.80 Mn |
| Mar 31, 2014 | 1.80 Mn |
| Dec 31, 2013 | 1.80 Mn |
| Dec 31, 2013 | 1.80 Mn |